Following a full submission
AWMSG advice |
|||
| Status: Recommended | |||
Fluticasone furoate / vilanterol (as trifenatate) (Relvar® Ellipta®) is recommended as an option for use within NHS Wales for the symptomatic treatment of adults with chronic obstructive pulmonary disease with a FEV1< 70% predicted normal (post-bronchodilator) with an exacerbation history despite regular bronchodilator therapy. |
|||
|
|||
Medicine details |
|||
| Medicine name | fluticasone furoate/vilanterol (as trifenatate) (Relvar® Ellipta®) | ||
| Formulation | 92 micrograms / 22 micrograms inhalation powder | ||
| Reference number | 1534 | ||
| Indication | Symptomatic treatment of adults with chronic obstructive pulmonary disease, with a FEV1 < 70% predicted normal (post-bronchodilator) with an exacerbation history despite regular bronchodilator therapy |
||
| Company | GlaxoSmithKline | ||
| BNF chapter | Respiratory system | ||
| Assessment type | Full | ||
| Status | Recommended | ||
| Advice number | 1014 | ||
| NMG meeting date | 09/04/2014 | ||
| AWMSG meeting date | 07/05/2014 | ||
| Ratification by Welsh Government | 23/05/2014 | ||
| Date of issue | 27/05/2014 | ||
| Date of last review | 08/05/2017 | ||